Vimian Group AB (publ) (VIMIAN) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. This is Patrick speaking, and thank you very much for joining us on our quarterly call today. We'll just jump right into it and talk a little bit about our highlights for the quarter. First and foremost, we delivered a strong earnings growth in the quarter. We're very pleased about how that developed and we'll talk a little bit more about where it came from and how it came to be. And as you might recall from our last time we met, we signaled that our organic revenue growth was going to be impacted by the adjustment in the annual program. Therefore, our organic growth is a bit lower than you might have expected and see us do in the past. The remaining operating units that we have, the three others, all deliver double digit organic growth in the quarter. And we also passed a very significant milestone here a few weeks ago when we started to trade on the large cap market on the Nasdaq main market here in Stockholm. It's a very important milestone for us as a publicly traded company. And in general terms and overall, we are very well positioned. We're in an attractive market. And there's some fundamental underlying growth factors there that we really like and we continue to see positive that. And we're also an agile business with an opportunity to steer and change our business as our world around us is uncertain and change. With that, let's go and dive a little bit deeper into the numbers for the quarter. We delivered 18% revenue growth to 107 and a half million euros. Organic growth ended up being 4%, again, negatively impacted by the adjustment in the annual order program, which is limited to our med tech orthopedic business in the US. The other segments delivered double digit growth. Our adjusted EBITDA for the quarter also grew 18% to 28.3 million. Our ...